Cargando…

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

BACKGROUND: Lymph node (LN) status is the most important prognostic variable used to guide ER positive (+) breast cancer treatment. While a positive nodal status is traditionally associated with a poor prognosis, a subset of these patients respond well to treatment and achieve long-term survival. Se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cockburn, Jessica G., Hallett, Robin M., Gillgrass, Amy E., Dias, Kay N., Whelan, T., Levine, M. N., Hassell, John A., Bane, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964078/ https://www.ncbi.nlm.nih.gov/pubmed/27469239 http://dx.doi.org/10.1186/s12885-016-2501-0

Ejemplares similares

Claudin-Low Breast Cancer; Clinical & Pathological Characteristics
por: Dias, Kay, et al.
Publicado: (2017)

A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer
por: Hallett, Robin M., et al.
Publicado: (2012)

Identification and evaluation of network modules for the prognosis of basal-like breast cancer
por: Hallett, Robin M., et al.
Publicado: (2015)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts
por: Gwynne, William D, et al.
Publicado: (2017)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

A program to identify prognostic and predictive gene signatures
por: Chorlton, Sam D, et al.
Publicado: (2014)

An algorithm to discover gene signatures with predictive potential
por: Hallett, Robin M, et al.
Publicado: (2010)

Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
por: Sohn, Guiyun, et al.
Publicado: (2016)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023)

Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
por: Park, Y, et al.
Publicado: (2009)

Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer
por: Cai, Hao, et al.
Publicado: (2015)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

Suicidality and Illness Course Worsening in a Male Patient with Bipolar Disorder during Tamoxifen Treatment for ER+/HER2+ Breast Cancer
por: Carmassi, Claudia, et al.
Publicado: (2021)

Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
por: Park, Y, et al.
Publicado: (2009)

Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
por: Moi, Line L Haugan, et al.
Publicado: (2012)

Predictors of positive axillary lymph nodes in breast cancer patients with metastatic sentinel lymph node
por: Callejo, IP, et al.
Publicado: (2005)

Methylation signature of lymph node metastases in breast cancer patients
por: Barekati, Zeinab, et al.
Publicado: (2012)

Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases
por: Benbrook, Doris Mangiaracina, et al.
Publicado: (2022)

EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer
por: Ye, Peng, et al.
Publicado: (2022)

Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer
por: Gu, Yu, et al.
Publicado: (2016)

Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours
por: Shenouda, Mira M., et al.
Publicado: (2017)

Arm lymphoscintigraphy after axillary lymph node dissection or sentinel lymph node biopsy in breast cancer
por: Sarri, Almir José, et al.
Publicado: (2017)

Nomograms Involving HER2 for Predicting Lymph Node Metastasis in Early Gastric Cancer
por: Mei, Yu, et al.
Publicado: (2021)

Factors Influencing Lymph Node Positivity in HER2/neu+ Breast Cancer Patients
por: Englander, Katherine, et al.
Publicado: (2023)

Tamoxifen-independent Cre-activity in SMMHC-CreER(T2) mice
por: Steffensen, L.B., et al.
Publicado: (2022)

Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes
por: Kochi, Mitsugu, et al.
Publicado: (2013)

HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
por: Han, Sanghoon, et al.
Publicado: (2020)

Fingerprinting Lymph Node Metastases
por: Symmans, W. Fraser, et al.
Publicado: (2008)

E2F1 and KIAA0191 expression predicts breast cancer patient survival
por: Hallett, Robin M, et al.
Publicado: (2011)

Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer
por: Hallett, Robin M, et al.
Publicado: (2014)

A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen
por: Wang, Kang, et al.
Publicado: (2018)

Limitations of Tamoxifen Application for In Vivo Genome Editing Using Cre/ER(T2) System
por: Ilchuk, Leonid A., et al.
Publicado: (2022)

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
por: Law, Emily K., et al.
Publicado: (2016)

Comparison of the distribution of lymph node metastases compared to healthy lymph nodes in breast cancer
por: Borm, Kai J., et al.
Publicado: (2022)

A Nomogram for Identifying HR+/Her2− Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy
por: Yang, Hanzhao, et al.
Publicado: (2023)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_05bfmj81869avcjd3ev4vsdidt